Daniel E Nixon
Overview
Explore the profile of Daniel E Nixon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Baker J, Neuhaus J, Duprez D, Freiberg M, Bernardino J, Badley A, et al.
J Acquir Immune Defic Syndr
. 2012 Mar;
60(2):128-34.
PMID: 22421746
Background: HIV infection is associated with premature development of cardiovascular disease. Understanding the effects of HIV replication on endothelial dysfunction and platelet activation may identify treatment targets to reduce cardiovascular...
12.
Sandler N, Wand H, Roque A, Law M, Nason M, Nixon D, et al.
J Infect Dis
. 2011 Jan;
203(6):780-90.
PMID: 21252259
Background: Chronic human immunodeficiency virus (HIV) infection is associated with intestinal permeability and microbial translocation that contributes to systemic immune activation, which is an independent predictor of HIV disease progression....
13.
Nixon D, Landay A
Curr Opin HIV AIDS
. 2010 Oct;
5(6):498-503.
PMID: 20978393
Purpose Of Review: HIV infection is characterized by chronic immune system activation and inflammatory cytokine production. This review will highlight recent developments using plasma and cellular biomarkers of immune system...
14.
Baker J, Neuhaus J, Duprez D, Kuller L, Tracy R, Belloso W, et al.
J Acquir Immune Defic Syndr
. 2010 Oct;
56(1):36-43.
PMID: 20930640
Objectives: Among a subgroup of participants in the Strategies for Management of Antiretroviral Therapy (SMART) Trial that were naïve to antiretroviral therapy (ART) or off ART (6 months or longer)...
15.
Lifson A, Belloso W, Carey C, Davey R, Duprez D, El-Sadr W, et al.
HIV Clin Trials
. 2008 Jun;
9(3):177-85.
PMID: 18547904
Purpose: Describe processes and challenges for an Endpoint Review Committee (ERC) in determining and adjudicating underlying causes of death in HIV clinical trials. Method: Three randomized HIV trials (two evaluating...
16.
Masho S, Wang C, Nixon D
Ther Clin Risk Manag
. 2008 Jun;
3(6):1097-104.
PMID: 18516268
Highly active antiretroviral therapy has significantly reduced HIV-related morbidity and mortality. Increasingly, fixed-dose antiretroviral combinations with equal or greater potency than traditional antiretrovirals, along with fewer side effects, reduced toxicity,...
17.
Wang J, Nixon D, McVoy M
J Virol
. 2007 Dec;
82(5):2394-404.
PMID: 18094152
Herpesvirus DNA replication proceeds via concatemeric replicative intermediates that are comprised of head-to-tail-linked genomes. Genome maturation is carried out by the terminase, a protein complex that mediates both insertion of...
18.
Wang C, Masho S, Nixon D
Curr HIV/AIDS Rep
. 2006 Apr;
3(2):66-73.
PMID: 16608662
The current literature is controversial in providing evidence to determine the optimal time to initiate therapy among patients with HIV. However, there is evidence that initiating early treatment might provide...
19.
McVoy M, Nixon D
J Virol
. 2005 Aug;
79(17):11115-27.
PMID: 16103162
Herpesvirus genome maturation is a complex process in which concatemeric DNA molecules are translocated into capsids and cleaved at specific sequences to produce encapsidated-unit genomes. Bacteriophage studies further suggest that...
20.
Nixon D, McVoy M
J Virol
. 2004 Jan;
78(4):1623-35.
PMID: 14747528
The halogenated benzimidazoles BDCRB (2-bromo-5,6-dichloro-1-beta-D-riborfuranosyl benzimidazole riboside) and TCRB (2,5,6-trichloro-1-beta-D-riborfuranosyl benzimidazole riboside) were the first compounds shown to inhibit cleavage and packaging of herpesvirus genomes. Both inhibit the formation of...